Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare Group Co., Ltd., has achieved a significant milestone by completing China's first proton therapy treatment for choroidal malignant melanoma. This advancement offers a novel eye-preserving treatment option for this common intraocular malignancy, which traditionally required enucleation, leading to permanent blindness. Utilizing advanced pencil beam scanning proton therapy and real-time image guidance, the center ensures high-dose, precise irradiation of the target area while protecting critical neighboring structures. This development fills a crucial gap in the field and provides new hope for patients with this condition.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.